Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

por Heitmann, Jonas S., Schlenk, Richard F., Dörfel, Daniela, Kayser, Sabine, Döhner, Konstanze, Heuser, Michael, Thol, Felicitas, Kapp-Schwoerer, Silke, Labrenz, Jannik, Edelmann, Dominic, Märklin, Melanie, Vogel, Wichard, Bethge, Wolfgang, Walz, Juliane S., Große-Hovest, Ludger, Steiner, Martin, Jung, Gundram, Salih, Helmut R.
Publicado 2023